The volunteers would be the first to find out if the technology could deliver.
In September 2023, Neuralink opened the door to a threshold humanity has long imagined but never crossed — the surgical merging of human thought with machine action. Paralyzed patients, those robbed of movement by injury or disease, became the first candidates to carry a chip inside their skulls, translating intention into cursor and keystroke. The moment arrives not cleanly, but weighted with prior failures, animal deaths, and regulatory resistance — a reminder that the distance between vision and verified truth is measured not in ambition, but in time and consequence.
- Patients with quadriplegia and ALS are being recruited to have a robot surgically implant a chip into their brains — a procedure with no long-term human safety data to draw from.
- The road here was turbulent: the FDA rejected Neuralink's first application, a monkey died during trials, and federal investigators scrutinized the company's rush toward commercialization.
- Elon Musk had promised human trials at least four times since 2019, making the eventual FDA green light in May 2023 feel less like triumph and more like a hard-won concession from regulators.
- The PRIME Study commits participants to six years of monitoring — eighteen months of intensive visits, then five years of follow-up — with the modest initial goal of moving a cursor by thought alone.
- Even with $280 million in fresh funding and FDA approval secured, Neuralink must still clear additional regulatory hurdles before its implants could ever reach the broader public.
In September 2023, Neuralink began accepting applications from human patients — the first time the company would place its devices inside living human brains. The milestone came after an independent review board cleared the way for the PRIME Study, a six-year trial examining whether the technology is both effective and safe.
The trial targets people with severe paralysis: those with quadriplegia from spinal cord injury or those living with ALS. The concept is elegant in its ambition — a robot implants a chip into the brain's movement-intention region, which then reads electrical signals and translates thought into on-screen action. The initial benchmark is deliberately humble: moving a cursor or typing using thought alone. Participants would commit to eighteen months of clinic and home visits, followed by five years of follow-up.
The path here was neither smooth nor swift. Musk had predicted human trials at least four times since 2019. When Neuralink finally sought FDA approval in 2022, the agency rejected the application, citing risks of implant migration and tissue damage during removal. Employees told Reuters the company had been pressured toward rapid commercialization — a pressure linked to animal deaths and a federal investigation. In 2022, a monkey died during experiments meant to teach it to play Pong, drawing sharp public criticism.
The FDA ultimately approved human trials in May 2023, though its caution reflected the genuine uncertainty surrounding an unproven field. Before Neuralink's devices could reach the public, further regulatory review would be required. In the meantime, the company raised $280 million from Founders Fund, and Musk continued drawing inspiration from science fiction — specifically the concept of a "neural lace" imagined by author Iain Banks.
The volunteers stepping forward for the PRIME Study carry the full weight of that unresolved question: whether the technology can deliver on its promise, and whether the human brain is ready to meet the machine halfway.
Neuralink, the brain-implant company founded by Elon Musk, began accepting applications for human patients in September 2023, marking the first time the startup would surgically place its devices inside living human brains. The move came after an independent review board granted approval, clearing the way for what the company calls the PRIME Study—Precise Robotically Implanted Brain-Computer Interface—a six-year investigation into whether the technology works and whether it's safe.
The trial targets people living with severe paralysis: those with quadriplegia from cervical spinal cord injury or those diagnosed with ALS. The procedure itself is straightforward in concept. A robot would surgically implant a chip into the region of the brain responsible for movement intention. Once in place, the chip would read electrical signals from the brain and transmit them to software, translating thought into action on a screen. The initial goal is modest—allowing patients to move a computer cursor or type on a keyboard using only their thoughts.
Participants would commit to eighteen months of regular visits to clinics and their homes, followed by five years of follow-up appointments. Interested candidates could register through Neuralink's website. The company had been pursuing this vision for five years, though all previous testing had occurred in animals, not humans. That animal testing history weighed heavily on the company's credibility. In 2022, a monkey died during experiments designed to teach it to play Pong, one of the earliest video games ever created. The incident drew public criticism and raised questions about the company's methods.
Neuralink's path to human trials was longer and more complicated than Musk had predicted. He had forecast the start of human testing at least four times since 2019, but the company didn't formally request FDA approval until 2022. The agency rejected that initial application, citing concerns that parts of the implant could migrate to other regions of the brain and that removing the device might damage surrounding tissue. Employees later told Reuters that the company was rushing toward commercialization, a pressure that had contributed to animal deaths and triggered a federal investigation into the startup's practices.
The FDA eventually approved human trials in May 2023, though the agency's caution reflected genuine uncertainty about an emerging field. In 2021, the FDA had published guidance acknowledging that brain-computer interface technology was advancing rapidly but remained largely unproven in humans. Before Neuralink's implants could be sold to the general public, they would need to clear additional regulatory hurdles and demonstrate both safety and effectiveness over time.
Financially, the company had momentum. In the months before opening human recruitment, Neuralink raised $280 million in a funding round led by Founders Fund, a venture capital firm established by Peter Thiel, the PayPal co-founder. Musk himself drew inspiration from science fiction—biographer Walter Isaacson reported that the entrepreneur had been influenced by author Iain Banks's concept of a "neural lace," a fictional technology that could be implanted into the brain to connect all human thoughts to a computer.
Yet for all the ambition and capital behind Neuralink, the company remained unproven in the one arena that mattered most: human brains. The volunteers who signed up for the PRIME Study would be the first to find out whether the technology could deliver on its promise, and whether the risks were worth the potential reward.
Citações Notáveis
The initial goal being to grant people the ability to control a computer cursor or keyboard using their thoughts alone.— Neuralink company statement
Employees told Reuters the company is rushing to market, resulting in careless animal deaths and a federal investigation.— Reuters reporting on Neuralink employee accounts
A Conversa do Hearth Outra perspectiva sobre a história
Why does Neuralink need to test this in humans at all? Couldn't they have learned everything they needed from animal trials?
Animal trials can tell you whether a device works mechanically, but not how a human brain responds to it over months or years. The FDA rejected their first application because they couldn't prove the implant wouldn't migrate or cause damage when removed. Only human patients can answer those questions.
The monkey that died in 2022—does that make you skeptical about whether they're ready for this?
It should make everyone skeptical. Employees told Reuters the company was rushing, that corners were being cut. But the FDA approved them anyway, which suggests the agency weighed the potential benefit to paralyzed patients against the risks and decided it was worth trying.
What happens if the implant fails in a patient's brain?
That's the unknown. The device is designed to be removable, but the FDA worried that removal itself could damage tissue. The trial patients are accepting that risk in exchange for the possibility of regaining some control over their environment.
How long will it take to know if this actually works?
The trial runs six years. Eighteen months of intensive monitoring, then five years of follow-up. So we won't have real answers until 2029 or 2030 at the earliest.
Is Musk's involvement a help or a liability at this point?
Both. His money and attention got the company this far. But his track record of overpromising timelines—he said human trials would start years before they actually did—makes it harder to trust what he says about what's coming next.